Trial document




drksid header

  DRKS00005069

Trial Description

start of 1:1-Block title

Title

Longitudinal non-interventional observational study on Adherence, safety and tolerability of AVANZ® in adults and GRAZAX® and SLIToneULTRA® in adults and children (5 – 17 years) in patients with allergic Rhinoconjunctivitis in GErmany

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

LARGE

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Systematically recorded data on the conformity of patient behaviour to accepted treatment recommendations (adherence) and the treatment continuance over the planned overall duration of 3 years (persistence) for subcutaneous, tablet and sublingual specific immunotherapy with different preparations (AVANZ®/GRAZAX®/SLIToneULTRA®) in real-life are currently not available.
Aim of the study is, therefore, to record data on adherence during a 3-year treatment with subcutaneous specific immunotherapy (SCIT, AVANZ®) in adults, with grass immunotherapy tablet (grass AIT, GRAZAX®) and with drop-based sublingual immunotherapy (SLIT, SLIToneULTRA®) in adults and children (5 – 17 years) during routine treatment.
For that purpose the physician records the administrations of specific immunotherapy performed in his clinic during the 3-year treatment period and adverse events, if applicable and assesses the adherence and persistence of the patient during regular visits every 3 months.
The patient enters data in a patient questionnaire once a year for allergies with all year round symptoms and additionally for pollen allergies during the pollen season. The questionnaire consists of questions on his functional status, labor productivity and health care, of assessments on his benefit of therapy and on his satisfaction with treatment and on his symptoms.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

A non-interventional observational longitudinal study in adults (AVANZ®) and adults and children aged 5 – 17 years (GRAZAX®, SLIToneULTRA®) in order to obtain information about use of AVANZ®, GRAZAX®, and SLIToneULTRA® over 3 years of treatment in a real life setting. The number of patients to be included in the study will add to the existing safety data for the products.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00005069
  •   2013/07/04
  •   [---]*
  •   no
  •   Approved
  •   F-2013-20, Ethik-Kommission bei der Landesärztekammer Baden-Württemberg
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   J30.1 -  Allergic rhinitis due to pollen
  •   J30.3 -  Other allergic rhinitis
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Routine treatment with specific immunotherapy (AVANZ® or GRAZAX® or SLIToneULTRA®)
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Non-interventional
  •   Observational study
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Treatment
  •   Single (group)
  •   N/A
  •   No
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Adherence / persistence during the planned 3-year course of specific immunotherapy quantified by the proportion of completers considering treatment discontinuations due to adverse events or reasons definitely not related to treatment, frequency of re-prescriptions.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

Safety and tolerability during the planned 3-year course of treatment, application of measures to increase compliance, predictive factors for adherence/persistence, correlation with therapeutic effect, patient questionnaire for health care research

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • Doctor's Practice 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2013/06/17
  •   1500
  •   Multicenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   5   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Routine treatment with specific immunotherapy (AVANZ®/GRAZAX®/SLIToneULTRA®)

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

Contraindications of specific immunotherapy

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • ALK-Abelló Arzneimittel GmbH
    • Griegstrasse 75, Haus 25
    • D-22763  Hamburg
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • ALK-Abelló Arzneimittel GmbH, Clinical Development
    • Mr.  Dr. rer. nat.  Hendrik  Wolf 
    • Griegstrasse 75, Haus 25
    • D-22763  Hamburg
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • ALK-Abelló Arzneimittel GmbH, Clinical Development
    • Mr.  Dr.  Hendrik  Wolf 
    • Griegstraße 75, Haus 25
    • D-22763  Hamburg
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • ALK-Abelló Arzneimittel GmbH
    • Griegstrasse 75, Haus 25
    • D-22763  Hamburg
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting complete, follow-up complete
  •   2018/05/08
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.